Incorporation of pharmacogenomics into routine clinical practice: The clinical pharmacogenetics implementation consortium (CPIC) guideline development process

Current Drug Metabolism

Volumn 15, Issue 2, 2014, Pages 209-217

  Caudle, Kelly E ^a   Klein, Teri E ^b   Hoffman, James M ^a   Müller, Daniel J ^c,d   Whirl Carrillo, Michelle ^b   Gong, Li ^b   McDonagh, Ellen M ^b   Sangkuhl, Katrin ^b   Thorn, Caroline F ^b   Schwab, Matthias ^e,f   Agúndez, José A G ^g   Freimuth, Robert R ^h   Huser, Vojtech ⁱ   Lee, Ming Ta Michael ^j,k,l   Iwuchukwu, Otito F ^m   Crews, Kristine R ^a   Scott, Stuart A ⁿ   Wadelius, Mia ^o   Swen, Jesse J ^p   Tyndale, Rachel F ^c,d   Stein, C Michael ^m,q   Roden, Dan ^m,q   Relling, Mary V ^a   Williams, Marc S ^r   Johnson, Samuel G ^s,t   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY OF EXTREMADURA   (Spain)

^h MAYO CLINIC   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j RIKEN Center for Integrative Medical Sciences   (Japan)

^k INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^l CHINA MEDICAL UNIVERSITY   (Taiwan)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o UPPSALA UNIVERSITY   (Sweden)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^q VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r GEISINGER HEALTH SYSTEM   (United States)

^s UNIVERSITY OF COLORADO   (United States)

^t Clinical Pharmacy Services   (United States)

more..

Author keywords

Clinical practice guideline; Guideline; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ANTIRETROVIRUS AGENT; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; THIOPURINE METHYLTRANSFERASE; DRUG;

CLINICAL GENETICS; CLINICAL PRACTICE; CONFLICT OF INTEREST; EFFECT SIZE; ELECTRONIC MEDICAL RECORD; EPISTASIS; EVIDENCE BASED PRACTICE; GENE DRUG INTERACTION; GENE INTERACTION; GENETIC SCREENING; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION DISSEMINATION; INFORMATION RETRIEVAL; LABORATORY TEST; MEDICAL RECORD; MEDICAL SOCIETY; MEDICATION ERROR; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRACTICE GUIDELINE; PRESCRIPTION; PUBLICATION; REVIEW; RISK ASSESSMENT; STANDARD; STATISTICAL SIGNIFICANCE; VALIDITY; PROCEDURES;

GENETIC TESTING; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS';

EID: 84900854522     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200215666140130124910     Document Type: Review

References (23)

1. Relling, M. V.; Klein, T. E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Therapeut., 2011, 89 (3), 464-7.
2. Relling, M. V.; Gardner, E. E.; Sandborn, W. J.; Schmiegelow, K.; Pui, C. H.; Yee, S. W.; Stein, C. M.; Carrillo, M.; Evans, W. E.; Klein, T. E. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Therapeut., 2011, 89 (3), 387-91.
3. Scott, S. A.; Sangkuhl, K.; Gardner, E. E.; Stein, C. M.; Hulot, J. S.; Johnson, J. A.; Roden, D. M.; Klein, T. E.; Shuldiner, A. R. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Therapeut., 2011, 90 (2), 328-32.
4. Johnson, J. A.; Gong, L.; Whirl-Carrillo, M.; Gage, B. F.; Scott, S. A.; Stein, C. M.; Anderson, J. L.; Kimmel, S. E.; Lee, M. T.; Pirmohamed, M.; Wadelius, M.; Klein, T. E.; Altman, R. B. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Therapeut., 2011, 90 (4), 625-9.
5. Crews, K. R.; Gaedigk, A.; Dunnenberger, H. M.; Klein, T. E.; Shen, D. D.; Callaghan, J. T.; Kharasch, E. D.; Skaar, T. C. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Therapeut., 2012, 91 (2), 321-6.
6. Martin, M. A.; Klein, T. E.; Dong, B. J.; Pirmohamed, M.; Haas, D. W.; Kroetz, D. L. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Therapeut., 2012, 91 (4), 734-8.
7. Wilke, R. A.; Ramsey, L. B.; Johnson, S. G.; Maxwell, W. D.; McLeod, H. L.; Voora, D.; Krauss, R. M.; Roden, D. M.; Feng, Q.; Cooper-Dehoff, R. M.; Gong, L.; Klein, T. E.; Wadelius, M.; Niemi, M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Therapeut., 2012, 92 (1), 112-7.
8. Hershfield, M. S.; Callaghan, J. T.; Tassaneeyakul, W.; Mushiroda, T.; Thorn, C. F.; Klein, T. E.; Lee, M. T. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Therapeut., 2013, 93 (2), 153-8.
9. Hicks, J. K.; Swen, J. J.; Thorn, C. F.; Sangkuhl, K.; Kharasch, E. D.; Ellingrod, V. L.; Skaar, T. C.; Muller, D. J.; Gaedigk, A.; Stingl, J. C. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Therapeut., 2013, 93 (5), 402-8.
10. Leckband, S. G.; Kelsoe, J. R.; Dunnenberger, H. M.; George, A. L. Jr.; Tran, E.; Berger, R.; Muller, D. J.; Whirl-Carrillo, M.; Caudle, K. E.; Pirmohamed, M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clin. Pharmacol. Therapeut., 2013, 94(3), 324-8.
11. Relling, M. V.; Gardner, E. E.; Sandborn, W. J.; Schmiegelow, K.; Pui, C. H.; Yee, S. W.; Stein, C. M.; Carrillo, M.; Evans, W. E.; Hicks, J. K.; Schwab, M.; Klein, T. E., Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Therapeut., 2013, 93 (4), 324-5.
12. Scott, S. A.; Sangkuhl, K.; Stein, C. M.; Hulot, J. S.; Mega, J. L.; Roden, D. M.; Klein, T. E.; Sabatine, M. S.; Johnson, J. A.; Shuldiner, A. R., Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update. Clin. Pharmacol. Therapeut., 2013, 94(3), 317-23
13. Clinical Practice Guidelines We Can Trust. The National Academies Press: 2011.
14. Crews, K. R.; Cross, S. J.; McCormick, J. N.; Baker, D. K.; Molinelli, A. R.; Mullins, R.; Relling, M. V.; Hoffman, J. M. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm., 2011,68 (2), 143-50.
15. Wilke, R. A.; Xu, H.; Denny, J. C.; Roden, D. M.; Krauss, R. M.; McCarty, C. A.; Davis, R. L.; Skaar, T.; Lamba, J.; Savova, G. The emerging role of electronic medical records in pharmacogenomics. Clin. Pharmacol. Therapeut., 2011, 89 (3), 379-86.
16. Schildcrout, J. S.; Denny, J. C.; Bowton, E.; Gregg, W.; Pulley, J. M.; Basford, M. A.; Cowan, J. D.; Xu, H.; Ramirez, A. H.; Crawford, D. C.; Ritchie, M. D.; Peterson, J. F.; Masys, D. R.; Wilke, R. A.; Roden, D. M. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Therapeut., 2012, 92 (2), 235-42.
17. Whirl-Carrillo, M.; McDonagh, E. M.; Hebert, J. M.; Gong, L.; Sangkuhl, K.; Thorn, C. F.; Altman, R. B.; Klein, T. E. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Therapeut., 2012, 92 (4), 414-7.
18. Valdes, R., Payne, D.A. & Linder, M.W. Laboratory analysis and application of pharmacogenetics to clinical practice. The National Academy of Clinical Biochemistry (NACB) - Laboratory Medicine Practice Guidelines http://www.aacc.org/members/nacb/LMPG/ Pages/default.aspx#[Online], 2010.
19. Clinical Practice Guidelines:Directions for a New Program. The National Academies Press: 1990.
20. Setting Priorities for Clinical Practice Guidelines. The National Academies Press: 1995.
21. Guyatt, G. H.; Norris, S. L.; Schulman, S.; Hirsh, J.; Eckman, M. H.; Akl, E. A.; Crowther, M.; Vandvik, P. O.; Eikelboom, J. W.; McDonagh, M. S.; Lewis, S. Z.; Gutterman, D. D.; Cook, D. J.; Schunemann, H. J. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl), 53S-70S.
22. Hicks, J. K.; Crews, K. R.; Hoffman, J. M.; Kornegay, N. M.; Wilkinson, M. R.; Lorier, R.; Stoddard, A.; Yang, W.; Smith, C.; Fernandez, C. A.; Cross, S. J.; Haidar, C.; Baker, D. K.; Howard, S. C.; Evans, W. E.; Broeckel, U.; Relling, M. V. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Therapeut., 2012, 92 (5), 563-6.
23. Shuldiner, A. R.; Relling, M. V.; Peterson, J. F.; Hicks, K.; Freimuth, R. R.; Sadee, W.; Pereira, N. L.; Roden, D. M.; Johnson, J. A.; Klein, T. E. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clin. Pharmacol.Therapeut., 2013, 94(2), 207-10.